Clofoctol

From WikiProjectMed
Jump to navigation Jump to search
Clofoctol
Structural formula of clofoctol
Ball-and-stick model of the clofoctol molecule
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
Rectal (suppository)[1]
ATC code
Pharmacokinetic data
Bioavailability98%[1]
MetabolismHepatic glucuronidation[1]
ExcretionBiliary[1]
Identifiers
  • 2-[(2,4-dichlorophenyl)methyl]-
    4-(2,4,4-trimethylpentan-2-yl)phenol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.048.739 Edit this at Wikidata
Chemical and physical data
FormulaC21H26Cl2O
Molar mass365.34 g·mol−1
3D model (JSmol)
  • Clc1cc(Cl)ccc1Cc2cc(ccc2O)C(C)(C)CC(C)(C)C
  • InChI=1S/C21H26Cl2O/c1-20(2,3)13-21(4,5)16-7-9-19(24)15(11-16)10-14-6-8-17(22)12-18(14)23/h6-9,11-12,24H,10,13H2,1-5H3 checkY
  • Key:HQVZOORKDNCGCK-UHFFFAOYSA-N checkY
  (verify)

Clofoctol is a bacteriostatic antibiotic. It is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria.[1] It has been marketed in France till 2005 under the trade name Octofene and in Italy as Gramplus.[citation needed]

It is only functional against Gram-positive bacteria.[2]

It penetrates into human lung tissue.[3]

A French company, Apteeus had been developing clofoctol as a potential therapy against SARS-CoV-2 in 2020-2021, but eventually the repurposing of the drug was abandoned, due to a lack of volunteers.[4][5]

References

  1. ^ a b c d e "Gramplus" (in Italian). Studio Medico Torrino. July 25, 2007. Archived from the original on March 8, 2016. Retrieved 2007-08-10.
  2. ^ Combe J, Simonnet F, Yablonsky F, Simonnet G (1980). "[Clofoctol binding by the bacteria (author's transl)]". J Pharmacol (in French). 11 (4): 411–25. PMID 6782374.
  3. ^ Danesi R, Gasperini M, Senesi S, Freer G, Angeletti CA, Del Tacca M (1988). "A pharmacokinetic study of clofoctol in human plasma and lung tissue by using a microbiological assay". Drugs Exp Clin Res. 14 (1): 39–43. PMID 3391105.
  4. ^ "Pasteur Lille obtient 5 M€ de LVMH pour repositionner un ancien médicament, l'Octofene, sur le traitement du Covid" (in French). AEF info. October 13, 2020. Retrieved 2020-10-13.
  5. ^ "La piste clofoctol. Interview du Pr Xavier Nassif". Jim.fr. 13 September 2021.